A Phase 3, Multi-center, Randomized, Double-blind, Parallel-group, Placebo-controlled Clinical Trial to Evaluate the Efficacy and Safety of Sodium Oligomannate (GV-971) in Treatment of Mild to Moderate Alzheimer's Disease (GREEN MEMORY: GREen Valley 971 EvaluatioN Memory)

Status: Suspended

Phase of Trial: Phase III

Latest Information Update: 31 Dec 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sodium oligomannurarate (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Acronyms GREEN MEMORY
Sponsors Shanghai Green Valley Pharmaceutical

Most Recent Events

18 Nov 2022 Status changed from recruiting to suspended.
16 Oct 2022 This trial has been discontinued in Poland (End Date: 6 July 2022) according to European Clinical Trials Database record.
06 Jul 2022 The trial has been completed in Czechia, according to European Clinical Trials Database record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight